BMS Consultant
Incyte Consultant
Novartis Consultant
D. MILOJOVIC BMS Speakers' Bureau
Incyte Speakers' Bureau
Novartis Speakers' Bureau, Scientific Advisory Bd.
Pfizer Research Support, Speakers' Bureau, Scientific Advisory Bd.
A. MULLALLY Actuate Therapeutics Research Support
Constellation Scientific Advisory Bd.
Janssen Research Support, Consultant
PharmaEssentia Consultant
J. NANGALIA No affiliation
F. NICOLINI Incyte Biosciences Research Support, Speakers' Bureau, Scientific Advisory Bd.
Novartis Pharma Research Support, Scientific Advisory Bd.
Pfizer Scientific Advisory Bd.
Sun Pharma Ltd Consultant
F. PASSAMONTI Celgene Research Support, Speakers' Bureau, Scientific Advisory Bd.
Novartis Speakers' Bureau, Scientific Advisory Bd.
N. PEMMARAJU ASH
Communications Committee Committee
AbbVie Research Support, Other
Affymetrix Research Support, Other
ASCO Leukemia Advisory Panel Committee
Blueprint Medicines Consultant, Other
Bristol Myers Squibb Consultant
Celgene Other
Cellectis Research Support
Daiichi Sankyo Research Support
DAVA Oncology Other
ImmunoGen Consultant
Incyte Other
LFB Biotechnologies Other
MustangBio Other
Novartis Research Support, Other
Pacylex
Pharmaceuticals Consultant
Plexxikon Research Support
Roche Diagnostics Other
SagerStrong Foundation Other
Samus Therapeutics Research Support
Springer Science + Business MediaO LtLhCer
Stemline Therapeutics Research Support, Other
D. RADIA N/A
D. REA Incyte Scientific Advisory Bd.
Novartis Scientific Advisory Bd.
Pfizer Scientific Advisory Bd.
A. REITER Blueprint Consultant, Scientific Advisory Bd., Other
Celgene Consultant, Scientific Advisory Bd., Other
Incyte Consultant, Scientific Advisory Bd., Other
Novartis Pharma Consultant, Scientific Advisory Bd., Other
G. ROSTI BMS Research Support, Speakers' Bureau, Scientific Advisory Bd.
Incyte Research Support, Consultant, Speakers' Bureau, Scientific Advisory Bd.
Novartis Research Support, Consultant, Speakers' Bureau, Scientific Advisory Bd.
Pfizer Research Support, Consultant, Speakers' Bureau, Scientific Advisory Bd.
T. SACHA Angelini Speakers' Bureau, Scientific Advisory Bd.
Celgene Speakers' Bureau, Scientific Advisory Bd.
Novartis Speakers' Bureau, Scientific Advisory Bd.
SCIENTIFIC PROGRAMME
SESSION I
OPTIMIZING
CYTOREDUCTION
SESSION II
MANAGEMENT OF CML
WITH TKI
SESSION III
MPN RISK
STRATIFICATION
INCLUDING VASCULAR
EVENTS
DEBATE 1
INTERFERON ALPHA
SHOULD BE FRONT LINE
THERAPY IN ALL ET/PV
PATIENTS
ROUNDTABLE 1
INFECTIONS IN
MYELOPROLIFERATIVE
DISORDERS, INCLUDING
CML
ROUNDTABLE 2
PREGNANCY AND
PARENTING
DEBATE 2
ALLOGENEIC STEM CELL
TRANSPLANTATION
SHOULD BE CONSIDERED
THIRD LINE OPTION IN
CHRONIC PHASE CML
SESSION IV
EVOLVING THERAPIES
IN MYELOFIBROSIS
SESSION V
MANAGEMENT OF
ADVANCED AND UNUSUAL
DISEASE (MPN AND CML)
SESSION VI
TREATMENT FREE
REMISSION IN CML
KEYNOTE LECTURE
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FO R A POSTER
PRESENTATION
DISCLOSURES